Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Summer;9(3):171-6.

GnRH antagonist versus agonist in normoresponders undergoing ICSI: a randomized clinical trial in Iran

Ensieh Tehraninejad  1 , Akram Ghahghaei Nezamabadi  1 , Batool Rashidi  1 , Maryam Sohrabi  1 , Maryam Bagheri  1 , Fedyeh Haghollahi  1 , Elham Azimi Nekoo  1 , Mina Jafarabadi  1
Affiliations

GnRH antagonist versus agonist in normoresponders undergoing ICSI: a randomized clinical trial in Iran

Ensieh Tehraninejad et al. Iran J Reprod Med. 2011 Summer.

Abstract

Background: General concern is that the pregnancy rate is higher with GnRH-agonist as a protocol of pituitary suppression. GnRH-antagonist protocol provides a shorter period of administration and an easy flexible protocol.

Objective: In this study, the outcomes of GnRH agonist and antagonist in ICSI cycles are compared in normo responder patients.

Materials and methods: In this randomized clinical trial, 300 normoresponders undergoing ICSI were randomly divided to GnRh agonist (n=150) and GnRh antagonist (n=150) groups. The main outcome measurements were chemical, clinical and ongoing pregnancy rates (PR).

Results: The mean duration of stimulation were 9.6±1.6 and 8.2±1.6 days in agonist and antagonist groups respectively (p=0.001). The mean number of MII oocyte retrieved in agonist and antagonist groups were 7.7±4.0 and 6.9±4.3 respectively (p=0.03). There was no significant difference between two groups regarding mean number of gonadotrophin ampoules, follicles, occytes, total embryos and good quality embryos, OHSS incidence, and abortion rate. Chemical pregnancy rate was 35.3% in agonist and 39.3% in antagonist group. Clinical pregnancy rate was 35.3% in agonist and 34% in antagonist group. Ongoing pregnancy rate was 45 (31.3%) in agonist and 44 (29.3%) in antagonist group. There was no significant difference between two groups in pregnancy rates.

Conclusion: In this study antagonist protocol was shown to be an easy, safe and friendly protocol in Iranian normoresponder patients, having similar outcomes with standard agonist protocol but shorter period of stimulation.

Keywords: GnRH agonist; GnRH antagonist; IVF; Normoresponder.

PubMed Disclaimer

References

    1. Huirne JA, Homburg R, Lambalk CB. Are GnRH antagonist comparable to agonists for use in IVF? . Hum Reprod . 2007;22:2805–2813. - PubMed
    1. Loumaye E. The control of endogenous secretion of LH by gonadotrophin-releasing hormone agonists during ovarian hyperstimulation for invitro fertilization and embryo transfer. Hum Reprod. 1990;5:357–376. - PubMed
    1. Shapiro DB, Mitchell-Leef D. GnRH antagonist in in vitro fertilization: where we are now. Minerva Ginecol. 2003;55:373–388. - PubMed
    1. Tarlatzis BC, Kolibianakis EM. GnRH agonists vs antagonists. Best Pract Res Clin Obstet Gynaecol. 2007;21:57–65. - PubMed
    1. Al- Inany H, Aboulghar M. Gonadotophin-releasing Hormone antagonists in assisted conception: a Cochrane review. Hum Reprod. 2002;17:874–885. - PubMed

LinkOut - more resources